News

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

Research from investigators in Ontario, Canada suggests the plateau in rates of cardiovascular disease and hospitalizations among people with type 2 diabetes seen in the last decade is masking a growing income-based disparity.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

Using data from more than 2 million US adults with nonsurgical hospitalizations, a new study from the Mayo Clinic is sounding the alarm on the increased cardiovascular risk associated with developing sepsis.

In an effort to address unmet needs related to the accessibility of biosimilars globally, the WHO updates the guidelines to include more therapies in the category.

Sintilimab plus IBI305 showed a significant improvement in objective response rate, time to response, duration of response, and depth of response in unresectable HCC versus sorafenib.

Natalizumab PB006 is the first biosimilar monoclonal antibody developed for treating patients with multiple sclerosis (MS).

There is very little data on long-term outcomes from pediatric patients with inflammatory bowel disease treated with anti-TNF biosimilars.

An analysis of the UK Biobank suggests individuals with celiac disease had an incidence rate of 9.0 CVD cases per 1000 person years compared with 7.4 per 1000 person years in people with no celiac disease.

The FDA announced that Banana Boat Hair & Scalp Sunscreen was being recalled voluntarily by its company due to risk of benzene exposure to consumers.

Our latest cardiology case report features a woman in her 70s presenting to the hospital with 5 days of radiating chest pain. Check out the ECG and determine the correct diagnosis!

New research into atopic dermatitis treatment indicated that topical JAK inhibitors were safe and effective, although more research is needed regarding adverse effects.

Risankizumab is the latest biologic approved by the FDA and the first-ever IL-23A targeted therapy approved for the treatment of patients with Crohn's disease.

The January 2023 endocrinology month in review features coverage of the FDA’s approval of bexagliflozin, news surrounding semaglutide, and the introduction of an expert-led, diabetes-focused podcast to HCPLive Endocrinology.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

Dr. Ian Flinn says many patients opt for treatment with Bruton's tyrosine kinase (BTK) over combination therapy.

New data from the AHA 2023 Statistical Update suggest more people died from cardiovascular-related causes in 2020 than in any year since 2003.

The specific mechanisms involved in associations between air pollution and respiratory illness without viral infection are not understood, especially compared with those of respiratory viruses and asthma exacerbation.

The risk of diabetes was reduced by approximately 50% in both the vigorous and moderate aerobic exercise groups compared with the nonexercise group.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

A systematic review and meta-analysis of nearly 3 dozen published articles details the apparent increase in risk of cardiovascular disease and diabetes associated with a diagnosis of autism.

New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.

The 2 strains identified were highly similar and exhibited differences of only 2 single-nucleotide polymorphisms.

In this episode of Diabetes Dialogue, ours hosts discuss the clearance of Tidepool Loop, what is unique about the app’s customizability and compatibility with other diabetes technologies, and other top points for people with diabetes and members of the diabetes care team to consider with the technology moving into the future.

An FDA panel voted unanimously this week to support harmonizing an annual primary and booster dose, moving public health strategies to reflect the endemic course of COVID-19.

A lower DME resolution rate was associated with a thicker baseline CST and better baseline best-corrected visual acuity in eyes treated with aflibercept.

A new review shows a majority of COVID-19 randomized, controlled trial preprints have been published with changes to the components of the original findings.